Navigation Links
Event Alert: 'SPL R4 Compliance and its Impact on Regulatory Submission Processes'
Date:4/30/2009

Register for an Educational Webinar "How Organizations Can Make the Transition to SPL R4 Compliance," Hosted by Pilgrim Software and featuring Virtify, Inc.

CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Virtify, Inc. (www.virtify.com), the market leader in Enterprise Content Compliance solutions for life sciences, and Pilgrim Software (www.pilgrimsoftware.com), a provider of Enterprise Compliance and Quality Management (ECQM) software solutions, will host a complimentary Webinar on best practices in SPL R4 compliance and how organizations can make the necessary transitions required by the new June 2009 mandate. The Webinar will take place on Thursday, May 7th at 11:00 a.m. EDT and feature Dr. Satish Tadikonda, founder and president of Virtify, Inc. This Webinar is for all human health, animal health, biologics and vaccines organizations and medical device companies who are modifying in-house systems or evaluating new technologies to meet the new SPL R4 requirements. The webinar is designed as a "how to" primer on complying with SPL R4.

Attendees will learn about:

  • Best practices for complying with SPL R4
  • Accelerating the conversion process from SPL R3 submissions to SPL R4 submissions
  • Automating the information transfer to SPL XML structure
  • Managing the changes involved with SPL R4 and streamlining submissions planning, preparation and tracking
  • Performing in-depth validation and QC for SPL R4 information

Title: "Best Practices for SPL R4 Compliance for Life Sciences Companies - Are You Ready for the June 2009 Mandate?"

Presenter: Dr. Satish Tadikonda, founder and president, Virtify, Inc.

Date/Time: Thursday, May 7 at 11:00 am EDT

To Register: https://pilgrim.webex.com/pilgrim/onstage/g.php?t=a&d=483923144

About Dr. Tadikonda

Dr. Tadikonda is founder and president of Virtify, Inc. With 20+ years in the drug and medical device industries, Tadikonda has a deep understanding of drug discovery and development processes, significant experience with global clinical and regulatory submission standards, and has been actively involved in leading and participating in the development of electronic standards for the industry. Prior to Virtify, Tadikonda founded companies focused on electronic data capture and R&D systems integration and held senior management positions with leading companies in the pharmaceutical and medical device industries.

About Virtify

Virtify is the market leader in Enterprise Content Compliance solutions for Life Sciences. Organizations rely on Virtify solutions to reduce time-to-market, risk, and costs by managing and automating the complex regulatory compliance and content exchange requirements throughout the product life cycle. Virtify's easy-to-use Virtx software suite is the industry's only solution to provide a secure, collaborative web-based environment for managing regulated content throughout the entire continuum -- from pre-clinical through product registration to commercialization. The company plays a leadership role in the development of global regulatory standards and is an active participant in a variety of standards committees. Virtify's software products, combined with comprehensive professional services and deep domain expertise enhance quality and compliance for some of the world's leading life sciences companies.

Virtify is headquartered in Cambridge, Massachusetts (USA) with facilities in Europe and Asia. For more information, visit www.virtify.com

About Pilgrim Software, Inc.

Pilgrim Software, Inc. is a world-leading provider of Enterprise Compliance and Quality Management solutions for global organizations. Named 2007 & 2008 North American Enterprise Compliance & Quality Management Company of the Year by Frost & Sullivan, Pilgrim helps organizations manage industry and regulatory compliance, reduce manufacturing costs and improve customer satisfaction. For more information, visit Pilgrim Software's website at www.pilgrimsoftware.com.


'/>"/>
SOURCE Virtify, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
2. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
3. Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
4. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
5. Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
6. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
7. IEEE Celebrates Its 125th Anniversary Presenting Emerging, World Changing Technologies During Its Embracing Human Technology Interactions Media Event
8. The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment
9. Ecologists propose first prevention for white-nose syndrome death in bats
10. White Paper Details How DNA Sequencing Services Can Prevent Cleanroom Shutdowns at Medical Device and Pharmaceutical Manufacturers
11. AMPAC Fine Chemicals Receives the California Pollution Prevention Challenge Award Two Consecutive Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
Breaking Biology News(10 mins):